GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) is a hormone of the incretin family, secreted in response to nutrient ingestion, and plays a role in metabolic homeostasis. GLP-1 receptor agonist has a peripheral and a central action, including stimulation of glucose-dependent insulin secretion and insulin biosynthesis, inhibition of glucagon secretion and gastric emptying, and inhibition of food intake. Through their mechanism, their use in the treatment of type 2 diabetes has been extended to the management of obesity, and numerous trials are being conducted to assess their cardiovascular effect. Type 2 diabetes appears to share common pathophysiological mechanisms with the development of cognitive disorders, such as Alzheimer's and Parkinson's disease, related to insulin resistance. In this review, we aim to examine the pathological features between type 2 diabetes and dementia, GLP-1 central effects, and analyze the relevant literature about the effect of GLP-1 analogs on cognitive function of patients with type 2 diabetes but also without. Results tends to show an improvement in some brain markers (e.g. hippocampal connections, cerebral glucose metabolism, hippocampal activation on functional magnetic resonance imaging), but without being able to demonstrate a strong correlation to cognitive scores. Some epidemiological studies suggest that GLP-1 receptor agonists may offer a protective effect, by delaying progression to dementia when diabetic patients are treated with GLP-1 receptor agonists. Ongoing trials are in progress and may provide disease-modifying care for Alzheimer's disease and Parkinson's disease patients in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus
Whitmer, R. A. (2009) · JAMA · doi:10.1001/jama.2009.460 · Cited by 1,128
Makki, K., Froguel, P., & Wolowczuk, I. (2013) · ISRN Inflammation · doi:10.1155/2013/139239 · Cited by 1,085
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791
Alzheimer’s disease drug development pipeline: 2022
Cummings, J., Lee, G., Nahed, P., Kambar, M. E. Z. N., Zhong, K., Fonseca, J., & Taghva, K. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12295 · Cited by 665
Amyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587
Research works printed but not linked: 36
- Haroon, 2015, Risk of dementia in seniors with newly diagnosed diabetes: a population-based study, Diabetes Care, 38, 1868, 10.2337/dc15-0491 · DOI · Paper page
- Katon, 2015, Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study, JAMA Psychiatry, 72, 612, 10.1001/jamapsychiatry.2015.0082 · DOI · Paper page
- Ninomiya, 2014, Diabetes mellitus and dementia, Curr Diab Rep, 14, 487, 10.1007/s11892-014-0487-z · DOI · Paper page
- Bello-Chavolla, 2019, Pathophysiological mechanisms linking type 2 diabetes and dementia: review of evidence from clinical, translational and epidemiological research, Curr Diabetes Rev, 15, 456, 10.2174/1573399815666190129155654 · DOI · Paper page
- Kamal, 2014, Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation, CNS Neurol Disord Drug Targets, 13, 338, 10.2174/18715273113126660137 · DOI
- Akiyama, 2000, Inflammation and Alzheimer's disease, Neurobiol Aging, 21, 383, 10.1016/S0197-4580(00)00124-X · DOI · Paper page
- Taylor, 2013, Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease, Neurochem Int, 62, 803, 10.1016/j.neuint.2012.12.016 · DOI · Paper page
- Stojkovska, 2015, Parkinson's disease and enhanced inflammatory response, Exp Biol Med Maywood NJ, 240, 1387, 10.1177/1535370215576313 · DOI · Paper page
- Ferrario, 2018, Insulin-mediated synaptic plasticity in the CNS: anatomical, functional and temporal contexts, Neuropharmacology, 136, 182, 10.1016/j.neuropharm.2017.12.001 · DOI · Paper page
- Burillo, 2021, Insulin resistance and diabetes mellitus in Alzheimer's disease, Cells, 10, 1236, 10.3390/cells10051236 · DOI · Paper page
- Prasad, 2014, Diabetes mellitus and blood-brain barrier dysfunction: an overview, J Pharmacovigil, 02, 125
- (Pre)diabetes, brain aging, and cognition | Elsevier Enhanced Reader [Internet]. [cité 12 déc 2022]. Disponible sur: https://reader.elsevier.com/reader/sd/pii/S0925443908002524?token=F425B21093C1F6234EFBE639E52509E47ABFA998A6EF738FC4C1CBE76AAC90F3FA363314605565BF37A0761E6F4C7FEC&originRegion=eu-west-1&originCreation=20221212145438.
- Claxton, 2015, Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia, J Alzheimers Dis JAD, 44, 897, 10.3233/JAD-141791 · DOI · Paper page
- Reger, 2008, Intranasal insulin administration dose-dependently modulates verbal memory and plasma β-amyloid in memory-impaired older adults, J Alzheimers Dis JAD, 13, 323, 10.3233/JAD-2008-13309 · DOI · Paper page
- Craft, 2012, Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial, Arch Neurol, 69, 29, 10.1001/archneurol.2011.233 · DOI · Paper page
- Lin, 2013, Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study, J Intern Med, 273, 102, 10.1111/joim.12000 · DOI · Paper page
- Meneilly, 2016, Diabetes, dementia and hypoglycemia, Can J Diabetes, 40, 73, 10.1016/j.jcjd.2015.09.006 · DOI
- Yang, 2013, Molecular links between Alzheimer's disease and diabetes mellitus, Neuroscience, 250, 140, 10.1016/j.neuroscience.2013.07.009 · DOI · Paper page
- Prasad, 2019, AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease, Mol Cell Biochem, 459, 95, 10.1007/s11010-019-03553-4 · DOI
- Liu, 2021, Potential new therapeutic target for Alzheimer's disease: glucagon-like peptide-1, Eur J Neurosci, 54, 7749, 10.1111/ejn.15502 · DOI
- Neth, 2017, Insulin resistance and Alzheimer's disease: bioenergetic linkages, Front Aging Neurosci, 9, 345, 10.3389/fnagi.2017.00345 · DOI · Paper page
- Brundel, 2014, Brain imaging in type 2 diabetes, Eur Neuropsychopharmacol J, 24, 1967, 10.1016/j.euroneuro.2014.01.023 · DOI
- Bassil, 2014, Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?, Prog Neurobiol, 118, 1, 10.1016/j.pneurobio.2014.02.005 · DOI · Paper page
- Bae, 2017, The Role of glucagon-like peptide 1 (GLP1) in type 3 diabetes: GLP-1 controls insulin resistance, neuroinflammation and neurogenesis in the brain, Int J Mol Sci, 18, 2493, 10.3390/ijms18112493 · DOI · Paper page
- Hölscher, 2014, Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases, J Endocrinol, 221, T31, 10.1530/JOE-13-0221 · DOI · Paper page
- Mansur, 2017, Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study, J Affect Disord, 207, 114, 10.1016/j.jad.2016.09.056 · DOI · Paper page
- Perna, 2018, 12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with type-2 diabetes mellitus, Clin Pharmacol Adv Appl, 10, 141
- Watson, 2019, Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease, Behav Brain Res, 356, 271, 10.1016/j.bbr.2018.08.006 · DOI · Paper page
- Zhang, 2019, Olfactory dysfunction mediates adiposity in cognitive impairment of type 2 diabetes: insights from clinical and functional neuroimaging studies, Diabetes Care, 42, 1274, 10.2337/dc18-2584 · DOI
- Cheng, 2022, Enhancement of impaired olfactory neural activation and cognitive capacity by liraglutide, but not dapagliflozin or acarbose, in patients with type 2 diabetes: a 16-week randomized parallel comparative study, Diabetes Care, 10.2337/dc21-2064 · DOI
- Aviles-Olmos, 2014, Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease, J Park Dis, 4, 337
- Mullins, 2019, A Pilot study of exenatide actions in Alzheimer's disease, Curr Alzheimer Res, 16, 741, 10.2174/1567205016666190913155950 · DOI · Paper page
- Eren-Yazicioglu, 2021, Effect of exenatide use on cognitive and affective functioning in obese patients with type 2 diabetes mellitus: exenatide use mediates depressive scores through increased perceived stress levels, J Clin Psychopharmacol, 41, 428, 10.1097/JCP.0000000000001409 · DOI
- Nørgaard, 2022, Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers, Alzheimers Dement Transl Res Clin Interv, 8, e12268, 10.1002/trc2.12268 · DOI · Paper page
- Husain, 2019, Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 381, 841, 10.1056/NEJMoa1901118 · DOI · Paper page
- Nguyen, 2023, Diabetes Obes Metab, 25, 1614, 10.1111/dom.15009 · DOI
Cited by
West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., et al. (2026) · BMJ · doi:10.1136/bmj-2025-085304 · Cited by 174
“Beyond cardiometabolic health, there have been suggestions that WMM may be effective for the treatment of osteoarthritis 39 40 and the prevention of cognitive decline, 41 among other conditions.”
Obesity accelerates cardiovascular ageing
Ruperez, C., Madeo, F., de Cabo, R., Kroemer, G., & Abdellatif, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf216 · Cited by 73
Tang, B., Sjölander, A., Wastesson, J. W., Maura, G., Blotiere, P.-O., Szilcz, M., Mak, J. K. L., Qin, C., Alvarsson, M., Religa, D., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102689 · Cited by 57
Lecis, D., Prandi, F. R., Barone, L., Belli, M., Sergi, D., Longo, S., Muscoli, S., Romeo, F., Federici, M., Lerakis, S., et al. (2023) · Biomolecules · doi:10.3390/biom13121695 · Cited by 23
Metadata
- Authors
- Monney, M., Jornayvaz, F. R., & Gariani, K.
- Venue
- Diabetes & Metabolism
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 49
- Issue
- 5
- Pages
- 101470
- ISSN
- 1262-3636 (ISSN-L)
- OpenAlex
- W4386274913
- Cited by
- 91
- References
- 25
- FWCI
- 15.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes. https://app.cochat.ai/papers/10.1016/j.diabet.2023.101470
- The paper
- Monney, M., Jornayvaz, F. R., & Gariani, K. (2023). GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes. Diabetes & Metabolism. https://doi.org/10.1016/j.diabet.2023.101470
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.